Na Liu

Dr. Na Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZGZhenhui Guo
Zhenhui Guo
HYHeng Yin
Heng Yin
TWTong Wu
Tong Wu
SWShaofeng Wu
Shaofeng Wu
LLLingyun Liu
Lingyun Liu
NLNa Liu
Na Liu

26 December 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JZJie Zhao
Jie Zhao
JLJing Luo
Jing Luo
CDCuili Deng
Cuili Deng
YFYueying Fan
Yueying Fan
NLNa Liu
Na Liu
YDYuanming Diao
Yuanming Diao

1 June 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YQYuanyuan Qiao
Yuanyuan Qiao
CLCanzhe Li
Canzhe Li
CCChupeng Chen
Chupeng Chen
PWPeilin Wu
Peilin Wu
YYYibing Yang
Yibing Yang
JGJiangyong Gu
Jiangyong Gu
Background: Psoriasis is a chronic skin disease affected by genetic and autoimmunity. The traditional Chinese medicine, Compound Qingdai Capsule (CQC), has shown potential benefits in treating psoriasis in clinical settings. Despite its efficacy, the molecular mechanisms underpinning its therapeutic action remain unclear. Purpose: This study aimed to unravel the molecular mechanism of Compound Qingdai Capsule for psoriasis based on the psoriasis pathogenic pathway network, integrating multi-omics analysis, systems pharmacology, machine learning modeling, and animal experimentation. Methods: Psoriasis pathogenic pathway network was constructed through employing bioinformatics analysis and psoriasis-related multi-omics data mining. The ingredients of CQC were detected by UPLC-MS/MS, and target prediction was performed by systems pharmacology. Machine learning, including Lasso regression, Random Forest, and Support Vector Machine (SVM), were utilized to screen core targets of psoriasis. Molecular docking was employed to evaluate the binding affinity between ingredients and core targets. The expression levels of core targets were determined using qRT-PCR and ELISA. Results: Psoriasis-related datasets GSE201827 and GSE174763 were comprehensively analyzed to obtain 635 psoriasis-related genes. These genes were further enriched to elucidate signaling pathways involved, leading to the construction of psoriasis pathogenic pathway network. Utilizing UPLC-MS/MS, 29 main ingredients of CQC were characterized. CQC ingredients-targets network was constructed using these ingredients and their targets. Screening of CQC anti-psoriasis core targets using machine learning algorithm. Molecular docking confirmed good binding affinity between these targets and ingredients. Imiquimod (IMQ) induced psoriasis-like rat validated the anti-psoriasis effect of CQC by alleviating symptoms, reducing spleen and thymus index, and modulating the expressions of core targets at mRNA and protein levels. Conclusion: CQC effectively modulates the expression levels of AURKB, CCNB1, CCNB2, CCNE1, CDK1, and JAK3 through various ingredients, such as astilbin, salvianolic acid A, and engeletin, via multiple pathways, thereby alleviating psoriasis-like symptoms.

20 July 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MXMingxiang Xie
Mingxiang Xie
MZMiaomiao Zhang
Miaomiao Zhang
YQYuanyuan Qiao
Yuanyuan Qiao
YYYibing Yang
Yibing Yang
FXFuda Xie
Fuda Xie
JGJiangyong Gu
Jiangyong Gu

1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
CLCanzhe Li
Canzhe Li
KCKaihao Chen
Kaihao Chen
YQYuanyuan Qiao
Yuanyuan Qiao
PWPeilin Wu
Peilin Wu
CCChupeng Chen
Chupeng Chen
JGJiangyong Gu
Jiangyong Gu
The molecular basis underlying the clinical differentiation in treating psoriasis with syndromes of blood-heat or blood-stasis in traditional Chinese medicine remains unclear. This study employs an integrated multi-omics approach to explore the similarities and differences in the pathogenic mechanisms of these two syndromes, and to elucidate the molecular foundations of Compound Qingdai Capsule and Yinxiekang Pian, which are representative formulas for syndrome-specific treatment, thereby providing insights into the scientific connotation of syndrome differentiation and treatment. Multi-omics data were integrated with machine learning to identify genes differentiating the two syndromes of psoriasis. The therapeutic mechanisms were explored through network pharmacology and molecular docking. Finally, in vivo experiments involved constructing composite psoriasis models in SD rats by combining traditional Chinese medicine syndromes with imiquimod induction, and analyzing skin lesion tissues via qPCR and ELISA. After constructing the psoriasis pathway network and successfully establishing rat models, the research identified the characteristic genes of blood-heat syndrome psoriasis as GSK3B, MTOR and CDK4, and those of blood-stasis syndrome psoriasis as AKT1, TNF and STAT3. STAT1 was found to be a common characteristic gene of both syndromes, while LTBP1, PROS1, and ALDH16A1 were the differential genes for distinguishing the two syndromes. Finally, Compound Qingdai Capsule and Yinxiekang Pian were shown to reduce the mRNA and protein expressions of GSK3B, AKT1 and STAT1 to varying degrees. GSK3B and AKT1 are differentially expressed in blood-heat syndrome and blood-stasis syndrome psoriasis respectively, while STAT1 is a common inflammatory mediator for both. Compound Qingdai Capsule and Yinxiekang Pian respectively provide a theoretical basis for traditional Chinese medicine syndrome differentiation and treatment of psoriasis by intervening in the same or different inflammatory targets and signaling pathways.

2 February 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FXFuda Xie
Fuda Xie
MXMingxiang Xie
Mingxiang Xie
YYYibing Yang
Yibing Yang
WAWeizhen Ao
Weizhen Ao
TZTingxiu Zhao
Tingxiu Zhao
JGJiangyong Gu
Jiangyong Gu